Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.
Biomarker and diagnostic research for severe acute respiratory syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
15 clinical trials registered, 1 recruiting. Interventions under study include other interventions, drug therapy, and biologic therapy. Pipeline includes 1 PHASE4, 2 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04815096](https://clinicaltrials.gov/study/NCT04815096) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 8:32 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Imaging Immune Activation in COVID-19 |
PHASE2 |
CellSight Technologies, Inc. |
RECRUITING |
467 publications have been identified in PubMed for severe acute respiratory syndrome. Kisho has analyzed 162 by research type. Research spans Review / Meta-Analysis (32%), Epidemiology / Natural History (25%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 52 | 32% |
Disease patterns and progression | 40 | 25% |
Laboratory research | 27 | 17% |
Other research | 16 | 10% |
Patient case studies | 10 | 6% |
Testing and diagnosis research | 7 | 4% |
Clinical study results | 5 | 3% |
New treatment approaches | 5 | 3% |
Malino D (2026). [PMID: 41604546](https://pubmed.ncbi.nlm.nih.gov/41604546/). *Eur J Gastroenterol Hepatol*. [Diagnostic / Biomarker]
Reina-Alfonso I (2026). [PMID: 41999211](https://pubmed.ncbi.nlm.nih.gov/41999211/). *J Gerontol A Biol Sci Med Sci*. [Basic Science / Preclinical]
Martins YRA (2026). [PMID: 41810661](https://pubmed.ncbi.nlm.nih.gov/41810661/). *Epidemiol Serv Saude*. [Epidemiology / Natural History]
Chappell KJ (2026). [PMID: 41285172](https://pubmed.ncbi.nlm.nih.gov/41285172/). *J Infect Dis*. [Clinical Trial Publication]
Persson C (2026). [PMID: 41869879](https://pubmed.ncbi.nlm.nih.gov/41869879/). *J Infect Dis*. [Other]
Feng PI (2026). [PMID: 41863536](https://pubmed.ncbi.nlm.nih.gov/41863536/). *Emerg Infect Dis*. [Epidemiology / Natural History]
Choi YJ (2026). [PMID: 41778639](https://pubmed.ncbi.nlm.nih.gov/41778639/). *Viral Immunol*. [Basic Science / Preclinical]
Vityala Y (2026). [PMID: 41766240](https://pubmed.ncbi.nlm.nih.gov/41766240/). *Indian J Pharmacol*. [Basic Science / Preclinical]
Theo CH (2026). [PMID: 41914563](https://pubmed.ncbi.nlm.nih.gov/41914563/). *J Med Virol*. [Review / Meta-Analysis]
Leitão Henriques F (2026). [PMID: 42167314](https://pubmed.ncbi.nlm.nih.gov/42167314/). *Horm Metab Res*. [Epidemiology / Natural History]